ATE219942T1 - Therapeutische pulverformulierung zur pulmonaren anwendung, welche kristallines insulin enthält - Google Patents
Therapeutische pulverformulierung zur pulmonaren anwendung, welche kristallines insulin enthältInfo
- Publication number
- ATE219942T1 ATE219942T1 AT98907915T AT98907915T ATE219942T1 AT E219942 T1 ATE219942 T1 AT E219942T1 AT 98907915 T AT98907915 T AT 98907915T AT 98907915 T AT98907915 T AT 98907915T AT E219942 T1 ATE219942 T1 AT E219942T1
- Authority
- AT
- Austria
- Prior art keywords
- powder formulation
- drying
- containing crystalline
- use containing
- crystalline insulin
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000000843 powder Substances 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 3
- 102000004877 Insulin Human genes 0.000 title abstract 2
- 108090001061 Insulin Proteins 0.000 title abstract 2
- 229940125396 insulin Drugs 0.000 title abstract 2
- 230000002685 pulmonary effect Effects 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
- 238000001694 spray drying Methods 0.000 abstract 1
- 238000001291 vacuum drying Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK31997 | 1997-03-20 | ||
| PCT/DK1998/000108 WO1998042368A1 (en) | 1997-03-20 | 1998-03-20 | Therapeutic powder formulation for pulmonary administration, containing crystalline insulin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE219942T1 true ATE219942T1 (de) | 2002-07-15 |
Family
ID=8092222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98907915T ATE219942T1 (de) | 1997-03-20 | 1998-03-20 | Therapeutische pulverformulierung zur pulmonaren anwendung, welche kristallines insulin enthält |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0971729B1 (de) |
| JP (1) | JP2001518916A (de) |
| AT (1) | ATE219942T1 (de) |
| AU (1) | AU6611998A (de) |
| DE (1) | DE69806362T2 (de) |
| WO (1) | WO1998042368A1 (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999055310A1 (en) | 1998-04-27 | 1999-11-04 | Altus Biologics Inc. | Stabilized protein crystals, formulations containing them and methods of making them |
| US6211144B1 (en) | 1998-10-16 | 2001-04-03 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
| PT1121144E (pt) * | 1998-10-16 | 2002-11-29 | Novo Nordisk As | Preparados de insulina concentrada estavel para administracao pulmonar |
| US6635617B1 (en) | 1998-10-16 | 2003-10-21 | Novo Nordisk A/S | Insulin preparations for pulmonary delivery containing menthol |
| HUP0103606A3 (en) * | 1998-10-16 | 2002-05-28 | Novo Nordisk As | Insulin preparations for pulmonary delivery containing menthol |
| US6350432B1 (en) * | 1999-03-19 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Pressurized container having an aerosolized pharmaceutical composition |
| AU4450700A (en) * | 1999-04-27 | 2000-11-10 | Eli Lilly And Company | Insulin crystals for pulmonary administration |
| WO2001000674A1 (en) * | 1999-06-29 | 2001-01-04 | Eli Lilly And Company | Insulin crystals for pulmonary administration |
| AU5454200A (en) * | 1999-06-29 | 2001-01-31 | Eli Lilly And Company | Protamine-free insoluble acylated insulin compositions |
| US20040265238A1 (en) * | 2003-06-27 | 2004-12-30 | Imtiaz Chaudry | Inhalable formulations for treating pulmonary hypertension and methods of using same |
| KR101159559B1 (ko) | 2003-08-05 | 2012-06-26 | 노보 노르디스크 에이/에스 | 신규의 인슐린 유도체 |
| JP2006199589A (ja) * | 2003-09-03 | 2006-08-03 | Ltt Bio-Pharma Co Ltd | 生理活性タンパク質またはペプチドを含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる外用剤 |
| WO2005072803A1 (en) | 2004-01-16 | 2005-08-11 | Biodel, Inc. | Sublingual drug delivery device |
| US20080090753A1 (en) | 2004-03-12 | 2008-04-17 | Biodel, Inc. | Rapid Acting Injectable Insulin Compositions |
| US20090074882A1 (en) | 2005-12-28 | 2009-03-19 | Novo Nordisk A/S | Insulin compositions and method of making a composition |
| WO2008152106A1 (en) * | 2007-06-13 | 2008-12-18 | Novo Nordisk A/S | Pharmaceutical formulation comprising an insulin derivative |
| CA2738615A1 (en) | 2008-10-30 | 2010-05-06 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
| US9060927B2 (en) | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
| JP6049625B2 (ja) | 2010-10-27 | 2016-12-21 | ノヴォ ノルディスク アー／エス | 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療 |
| WO2014177623A1 (en) | 2013-04-30 | 2014-11-06 | Novo Nordisk A/S | Novel administration regime |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| CN114096269B (zh) | 2019-07-12 | 2024-06-11 | 诺和诺德股份有限公司 | 高浓度胰岛素制剂 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2933946A1 (de) * | 1979-08-22 | 1981-03-12 | Hoechst Ag, 6000 Frankfurt | Insulinkristallsuspension und verfahren zu ihrer herstellung. |
| IS1796B (is) * | 1993-06-24 | 2001-12-31 | Ab Astra | Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband |
| US5597893A (en) * | 1994-10-31 | 1997-01-28 | Eli Lilly And Company | Preparation of stable insulin analog crystals |
| SE9404468D0 (sv) * | 1994-12-22 | 1994-12-22 | Astra Ab | Powder formulations |
-
1998
- 1998-03-20 EP EP98907915A patent/EP0971729B1/de not_active Expired - Lifetime
- 1998-03-20 AU AU66119/98A patent/AU6611998A/en not_active Abandoned
- 1998-03-20 JP JP54474698A patent/JP2001518916A/ja active Pending
- 1998-03-20 WO PCT/DK1998/000108 patent/WO1998042368A1/en not_active Ceased
- 1998-03-20 DE DE69806362T patent/DE69806362T2/de not_active Expired - Fee Related
- 1998-03-20 AT AT98907915T patent/ATE219942T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE69806362D1 (de) | 2002-08-08 |
| EP0971729B1 (de) | 2002-07-03 |
| AU6611998A (en) | 1998-10-20 |
| EP0971729A1 (de) | 2000-01-19 |
| WO1998042368A1 (en) | 1998-10-01 |
| DE69806362T2 (de) | 2003-01-30 |
| JP2001518916A (ja) | 2001-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE219942T1 (de) | Therapeutische pulverformulierung zur pulmonaren anwendung, welche kristallines insulin enthält | |
| GB2240337B (en) | Aerosol carriers | |
| AU6611898A (en) | Method for preparation of a therapeutic powder through coprecipitation of insulin and absorption enhancer | |
| YU59092A (sh) | Formulacije aerosola koji ne sadrže hlorofluorougljenična jedinjenja | |
| CA2346791A1 (en) | Flow resistance modulated aerosolized active agent delivery | |
| KR970703366A (ko) | 인터페론의 건조 분말 제형물을 제조하기 위한 방법 및 조성물(methods and compositions for the dry powder formulation of interferons) | |
| YU59192A (sh) | Formulacija aerosola koje ne sadrže hlorofluorougljenična jedinjenja | |
| EE03221B1 (et) | Inhaleeritavad ravimpreparaadid, nende valmistamise protsess ja inhalaator nende kasutamiseks | |
| IS4179A (is) | Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband | |
| TW329387B (en) | Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate | |
| TR200002692T2 (tr) | Aerosol haline getirilen aktif maddenin verilmesi. | |
| NO20024708D0 (no) | Behandling av respiratoriske sykdommer | |
| BG102689A (bg) | Фармацевтичен аерозолен състав за използване при лечение на респираторни смущения | |
| CA2226657A1 (en) | Improvements in and relating to powders for use in dry powder inhalers | |
| ATE128350T1 (de) | Pharmazeutische aerosolformulierung. | |
| NO974618L (no) | Farmasöytiske preparater for intranasal administrasjon | |
| BR9709845B1 (pt) | preparaÇço aquosa de insulina, formulaÇço farmacÊutica parenteral, e, processso para aumentar a estabilidade quÍmica de uma preparaÇço de insulina. | |
| ATE137958T1 (de) | Pharmazeutische aerosolzubereitung sowie deren verwendung zur behandlung und prophylaxe viraler erkrankungen | |
| ATE417599T1 (de) | Pharmazeutische zubereitung zur intranasalen applikation von proteinen, enthaltend chitosan oder eines seiner derivate | |
| DE60202299D1 (de) | Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten | |
| WO2005041852A3 (en) | Keratin gel and the types 2, 4 and 6 of collagens of frog protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |